Evidence map›Paper›PMID 35628194›Full record

ArticleInternational journal of molecular sciences2022

Distinct Effects of Cannabidiol on Sphingolipid Metabolism in Subcutaneous and Visceral Adipose Tissues Derived from High-Fat-Diet-Fed Male Wistar Rats.

Klaudia Berk, Karolina Konstantynowicz-Nowicka, Tomasz Charytoniuk, Ewa Harasim-Symbor, Adrian Chabowski

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. The Role of Cannabidiol in Liver Disease: A Systemic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Klaudia BerkDepartment of Physiology, Medical University of Bialystok, 15-089 Bialystok, Poland.
Karolina Konstantynowicz-NowickaDepartment of Physiology, Medical University of Bialystok, 15-089 Bialystok, Poland.
Tomasz CharytoniukDepartment of Physiology, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-4593-7476
Ewa Harasim-SymborDepartment of Physiology, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0003-3507-4686
Adrian ChabowskiDepartment of Physiology, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-7407-8156
Medical University of Białystok · PL

Funding

Medical University of Bialystok SUB/1/DN/21/007/1118National Science Center 2017/26/D/NZ3/01119
6 · The paper itself

Abstract

Available data suggest that cannabidiol (CBD) may ameliorate symptoms of insulin resistance by modulating the sphingolipid concentrations in particular organs. However, it is not entirely clear whether its beneficial actions also involve adipose tissues in a state of overnutrition. The aim of the study was to evaluate the effect of CBD on sphingolipid metabolism pathways and, as a result, on the development of insulin resistance in subcutaneous (SAT) and visceral (VAT) adipose tissues of an animal model of HFD-induced insulin resistance. Our experiment was performed on Wistar rats that were fed with a high-fat diet and/or received intraperitoneal CBD injections. We showed that CBD significantly lowered the ceramide content in VAT by reducing its de novo synthesis and increasing its catabolism. However, in SAT, CBD decreased the ceramide level through the inhibition of salvage and de novo synthesis pathways. All of these changes restored adipose tissues' sensitivity to insulin. Our study showed that CBD sensitized adipose tissue to insulin by influencing the metabolism of sphingolipids under the conditions of increased availability of fatty acids in the diet. Therefore, we believe that CBD use may be considered as a potential therapeutic strategy for treating or reducing insulin resistance, T2DM, and metabolic syndrome.

Indexed as

CannabidiolInsulin ResistanceAnimalsCeramidesDiet, High-FatInsulinMaleRatsRats, WistarSphingolipidsCannabidiolCeramidesInsulinSphingolipidsadipose tissuecannabidiolceramideinsulin resistancesphingolipids

Identifiers

PMID35628194
PMCPMC9142011
OpenAlexW4280580899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.